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Histone deacetylases (HDACs)—an enzyme family that deacetyl-
ates histones and non-histone proteins—are implicated in human
diseases such as cancer, and the first-generation of HDAC
inhibitors are now in clinical trials. Here, we report the 2.0 A˚
resolution crystal structure of a catalytically inactive HDAC8
active-site mutant, Tyr306Phe, bound to an acetylated peptidic
substrate. The structure clarifies the role of active-site residues in
the deacetylation reaction and substrate recognition. Notably,
the structure shows the unexpected role of a conserved residue at
the active-site rim, Asp 101, in positioning the substrate by
directly interacting with the peptidic backbone and imposing a
constrained cis-conformation. A similar interaction is observed in
a new hydroxamate inhibitor–HDAC8 structure that we also
solved. The crucial role of Asp 101 in substrate and inhibitor
recognition was confirmed by activity and binding assays of
wild-type HDAC8 and Asp101Ala, Tyr306Phe and Asp101Ala/
Tyr306Phe mutants.
Keywords: HDAC; acetylated substrate; mutagenesis;
crystallography; drug design
EMBO reports (2007) 8, 879–884. doi:10.1038/sj.embor.7401047
INTRODUCTION
Acetylation is a post-translational modification that controls the
biological function and stability of proteins in eukaryotic cells.
Unlike a-amino-terminal acetylation, e-amino-lysine acetylation
is reversible. Acetylation status of the lysine residue at the
N-terminal extensions of core histones is controlled by two
counteracting enzymes: histone acetyl transferases and histone
deacetylases (HDACs; Roth et al, 2001; Marks et al, 2003). These
activities affect histone–DNA interactions and their recognition by
other chromatin-binding proteins. However, HDACs also partici-
pate in the regulation of non-histone proteins and are therefore
important in many biological processes such as cell-cycle
progression, cell survival and differentiation (Di Gennaro et al,
2004). As these processes are modulated during malignant
transformation, HDAC inhibitors are being developed as anti-
neoplastic drugs (Gallinari et al, 2007), and vorinostat was
recently approved by the Food and Drug Administration for the
treatment of cutaneous T-cell lymphoma.
Eukaryotic HDACs have been classified into four groups on the
basis of phylogenetic analysis (Gregoretti et al, 2004). Class I
HDACs include 1–3 and 8 (homologous to yeast Rpd3) and class II
HDACs include 4–7, 9 and 10 (homologous to yeast Hda1), which
are divided into two subclasses: IIa (4, 5, 7, 9) with one catalytic
domain and IIb (6, 10) with two catalytic domains. HDAC11 is
distinct from those in classes I and II; therefore, it has been placed
in class IV, as class III refers to the unrelated sirtuin deacetylases
(Blander & Guarente, 2004). HDACs 1–11 are metalloenzymes
that require zinc for deacetylation; HDACs in classes I and IV are
350–500 residues in length, whereas class II HDACs are about
1,000 residues long. However, they all have homologous catalytic
sites and are considered to go through a similar reaction
mechanism (Holbert & Marmorstein, 2005).
With the exception of HDAC8, functional HDACs are not
found as single polypeptides, but as high-molecular-weight
multiprotein complexes (Yang & Seto, 2003), and most purified
recombinant HDACs are enzymatically inactive (Sengupta & Seto,
2004). Therefore, from a structural biology perspective, HDAC8 is
the best model among mammalian HDACs. Indeed, the crystal
structure of HDAC8 in complex with inhibitors was recently
solved and showed a compact a/b-domain composed of a central
eight-stranded parallel b-sheet flanked by 11 a-helices (Somoza
et al, 2004; Vannini et al, 2004), similar to the bacterial HDAC-
like protein HDLP (Finnin et al, 1999) and the bacterial HDAC-
like amidohydrolase HDAH (Nielsen et al, 2005). The HDAC8
active site (Somoza et al, 2004; Vannini et al, 2004) presents
features of both serine and zinc proteases, and contains two
His–Asp dyads with both histidine residues supposed to work as a
general acid–base catalytic pair, as originally proposed for HDLP
and extended to HDAH (Finnin et al, 1999; Nielsen et al, 2005).
However, this mechanism has been questioned by theoretical
studies, which indicate that the simultaneous protonation of both
histidine residues is unlikely (Vanommeslaeghe et al, 2005).
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Moreover, a different type of mechanism with Tyr306, as a
nucleophile, has been suggested (Kapustin et al, 2003).
To gain structural insights into acetylated substrate recognition
and to clarify the deacetylation reaction, the structure of human
HDAC8 in complex with a p53-derived diacetylated peptide,
(acetyl)-L,Arg-L,His-L,Lys(e-acetyl)-L,Lys(e-acetyl), containing a
fluorogenic coumarin group at its carboxyl terminus, was
determined using X-ray crystallography at a resolution of 2.0 A˚.
In addition, we solved an HDAC8 structure in complex with a
large hydroxamate inhibitor, (2S )-N8-hydroxy-2-{[(5-methoxy-2-
methyl-1H-indol-3-yl)acetyl]amino}-N1-[2-(2-phenyl-1H-indol-3-yl)
ethyl]octanediamide, at a resolution of 2.25 A˚ (supplementary
Table S1 online).
RESULTS AND DISCUSSION
The substrate used for structural studies corresponds to the
sequence Arg379-His380-Lys381(e-acetyl)-Lys382(e-acetyl) of
the p53 tumour suppressor protein, localized in the C-terminal,
basic regulatory domain of p53 (Liu et al, 1999). Lys382
deacetylation by class I HDACs results in repression of the
transcriptional activity of p53 (Vaghefi & Neet, 2004). To trap the
substrate in the crystal, we engineered a catalytically inactive
HDAC8 mutant, Tyr306Phe (supplementary Fig S1 online). The
overall structure of the complex shows a dimeric arrangement
(Fig 1A,B), similar to HDAC8 structures with small hydroxamic
acids, named compound 1 (Vannini et al, 2004) and Cra-19156
(Somoza et al, 2004). The main difference compared with these
structures is the ordering of exposed loop regions, residues
84–105, following substrate binding, which produces a more
compact protein conformation (supplementary Fig S2 online). The
same dimeric arrangement and ordering of loop regions
are observed in our new HDAC8–inhibitor structure (Fig 2;
supplementary Table S1 online).
The structure of the monomer shows Lys382(e-acetyl)—
Lys4(Ac) of the substrate—protruding into the narrow cavity of
the active site and coordinating Zn2þ through its carbonyl oxygen
(Fig 1C). This lysine residue corresponds to the one deacetylated
in p53 by class I HDACs (Vaghefi & Neet, 2004). In addition, there
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Fig 1 | Structure of the human HDAC8–substrate complex. (A) Ribbon diagram of the two HDAC8–substrate complexes in the asymmetric unit.
The substrate and residues involved in the head-to-head packing are shown in a stick representation. Carbon, oxygen and nitrogen for the substrate
are green, red and blue, respectively. Zn2þ and Kþ ions are represented as purple spheres. (B) Enlarged view of the substrate-binding site in the
asymmetric unit with the 1.0s-contoured 2FoFc electron density map. (C) HDAC8 monomer with the bound substrate. Atoms are coloured as in (A).
(D) Enlarged view of the active site. Polar interactions are shown as dashed yellow lines. HDAC, histone deacetylase.
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is one water molecule that is Zn2þ -coordinated and interacts with
His142 and His143, which is on the opposite side of the substrate
with respect to residue 306 (Fig 1D). His142 is part of the buried
and conserved charge–relay system, whereas His143 is part of the
exposed putative charge–relay system, which is not conserved in
HDACs (supplementary Fig S3 online). Therefore, Zn2þ is penta-
coordinated with Asp178 (Od2, 1.97 A˚), His180 (Nd1, 2.07 A˚)
and Asp267 (Od2, 1.97 A˚) as ligands, in addition to the water
(2.07 A˚) and the carbonyl oxygen (2.02 A˚) of the acetyl group of
the substrate (Fig 1D). The carbonyl carbon of the substrate is in
close proximity to this active-site water molecule (2.34 A˚) and
also to the catalytic Zn2þ that polarizes the carbonyl group and
orientates the water molecule, the nucleophilicity of which is
increased further by hydrogen bonding to His142 and His143. The
alkyl chain of Lys4(Ac) is also stabilized by hydrophobic
interactions with Phe152 and Phe208, and one hydrogen bond
to Gly151 (Fig 1D). In the structure of the HDAC8–inhibitor
complex, the hydroxamate moiety establishes hydrogen bonds
with His142, His143 and Tyr306, and coordinates Zn2þ in a
bidentate fashion, with one of the oxygen atoms replacing the
active-site water molecule (Fig 3A). The inhibitor-linker region fits
in the hydrophobic channel and makes apolar interactions with
Phe152 and Phe208, and van der Waals interactions with the
main chain of Gly151 (Fig 3A). In HDACs there is a strict
conservation of those residues contacting the Lys4(Ac) of the
substrate or the hydroxamate–linker moieties of the inhibitor
(supplementary Fig S3 online). The only significant exception is
Tyr306, which is histidine in class IIa HDACs (4, 5, 7, 9), which
causes a pronounced decrease in catalytic activity on peptidic
substrates (Fischle et al, 2002).
Deacetylation should start with the nucleophilic attack by the
active-site water molecule on the carbonyl carbon of the substrate
(Fig 1D); His142 is suitably poised to abstract a proton from this
water molecule. The interaction of the carbonyl oxygen of the
substrate with Zn2þ results in enhanced polarization of the
carbonyl bond, and hence is more susceptible to a nucleophilic
attack. This mechanism is in agreement with what was previously
proposed (Finnin et al, 1999; Somoza et al, 2004; Vannini et al,
2004; Nielsen et al, 2005), and excludes the role of residue
306 as a water-activated nucleophile (Kapustin et al, 2003;
Vanommeslaeghe et al, 2003) because the active-site water
molecule is far away from residue 306 and is on the opposite
side with respect to the acetylated lysine (Figs 1D,3A). On
nucleophilic attack—if we consider no rearrangement at the
active site—His143 should be further away to protonate the
amine-leaving group (Ne2—Nz 3.79 A˚), whereas Tyr306-hydroxyl
group (Fig 3A) would be at a closer distance to donate a proton to
the amine. The intermediate would then break, yielding acetate
and lysine products. Here, by mutating Tyr306 to phenylalanine
the substrate is bound but not hydrolysed, as the amino group of
the intermediate is unable to be stabilized by binding to the
tyrosine-hydroxyl, and is therefore trapped in the active site.
Tyr306 is essential for activity on the peptidic substrate and also
on purified histones (Fig 4A; supplementary Fig S1 online).
Instead, the non-conservation of the exposed charge–relay system
(His143/Asp183, Asn or Gln; supplementary Fig S3 online), the
suggestion of recent theoretical studies of HDAC protonated at
His142 but not at His143 (Vanommeslaeghe et al, 2005) and the
finding that His143 mutation in HDAC1 reduced but did not
abolish activity (Hassig et al, 1998) indicate a possible role of
His143 in orientating the substrate rather than a role in
protonating the amine-leaving group (Finnin et al, 1999; Somoza
et al, 2004; Vannini et al, 2004; Nielsen et al, 2005).
An unexpected feature of this structure is at the rim of the active
site, in which the side-chain carboxylate of Asp101 establishes
two directional hydrogen bonds with two adjacent nitrogen atoms
of the substrate backbone, constraining the latter in an unusual
cis-conformation (Fig 3B). In addition, the two main-chain oxygen
atoms of the substrate form a network of water-mediated hydrogen
bonds with several protein residues (Fig 3B). Presumably, the tight
polar interactions observed at the rim of the active site keep the
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Fig 2 | Structure of the human HDAC8–inhibitor complex. (A) The
hydroxamate inhibitor. (B) The two monomers in the asymmetric unit
are in grey and yellow, respectively. The inhibitor and residues involved
in the head-to-head packing are shown in a stick representation. Carbon,
oxygen and nitrogen for the inhibitor are cyan, red and blue,
respectively. (C) An enlarged view of the inhibitor-binding site in the
asymmetric unit with 1.0s-contoured 2FoFc electron density map.
HDAC, histone deacetylase.
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substrate in place during the deacetylation reaction. To confirm
the relevance of this interaction, we mutated Asp101 to alanine.
This mutation resulted in a complete loss of enzyme activity on the
peptidic substrate and also on purified histones, despite the fold
conservation (Fig 4A; supplementary Fig S1 online), indicating that
this interaction is required for the correct positioning of substrates.
In previous HDAC8 structures (Somoza et al, 2004; Vannini et al,
2004), the loop containing Asp101 (residues 98–105) is a region of
high mobility with poor electron density. On substrate binding,
this loop becomes structured (supplementary Fig S2 online,
A compared with B and C). The importance of Asp101 in ancho-
ring the substrate is not an exclusive feature of HDAC8, but might
be extended to the whole family owing to the strict conservation
of this residue in all class I and class II HDACs, despite the low
overall sequence homology in this loop region and the presence of
a long insertion in class IIa HDACs (supplementary Fig S3 online).
Furthermore, it is important to note that, in the structure of the
HDAC8–inhibitor complex, the same interaction with Asp101 is
retained by the two inhibitor amide groups, despite the different
conformer for the side chain of Tyr100 (Fig 3C). As a result of
this interaction and differently from previous HDAC8-inhibited
structures (supplementary Fig S2B,C online), in the structure
reported here (Fig 2), these loop residues are all in density.
To validate further the role of Asp101, we carried out other
biochemical experiments. In addition to the Asp101A mutant, we
also produced the double mutant Asp101Ala/Tyr306Phe, which,
as expected, was completely inactive (Fig 4A). Furthermore, the
influence of the inhibitor and the peptidic substrate on the thermal
stability of all mutants, and also on the wild-type protein, was
evaluated by far-UV circular dichroism (CD) spectroscopy
(supplementary information online). Only for wild-type HDAC8
did the thermal stability increase in the presence of the inhibitor
(DTm¼ 6.1 1C; Fig 4B), whereas only for the Tyr306Phe mutant
incubated with the peptidic substrate was there an increase in Tm
A
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Fig 3 | Comparison of the structure of HDAC8–substrate with that of the HDAC8–hydroxamate inhibitor. (A) View of the substrate-binding site
superimposed with the structure of the HDAC8–inhibitor (r.m.s.d.-Ca, 0.315 A˚). Oxygen, nitrogen and carbon of the inhibitor are red, blue and cyan,
respectively. Protein is cyan in the HDAC8–inhibitor structure. (B) Molecular surface of the HDAC8–substrate complex at the active-site entrance.
Water molecules are shown as red spheres. (C) Molecular surface of the HDAC8–inhibitor complex. HDAC, histone deacetylase.
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(DTm¼ 9 1C; Fig 4B). These results confirm the relevance of
Asp101 interactions (Fig 3B,C). We also carried out direct binding
assays between all HDAC8 proteins and the inhibitor by surface
plasmon resonance (SRP) experiments (Fig 4C–E; supplementary
information online). These experiments were not possible with the
substrate owing to the high Km of the wild-type protein (67 mM),
whereas the inhibitor had an HDAC8 IC50 of 100 nM (see
supplementary information online). This IC50 is in line with the
Kd measured by SRP (220 nM). The Tyr306Phe mutant had a
strong decrease in the rate of complex formation (kon) with the
inhibitor, without much affecting the rate of dissociation (koff;
Fig 4D compared with C). The opposite was found for the
Asp101Ala mutant that had a high koff, but a kon similar to that of
the wild-type protein (Fig 4E compared with C), again indicating
the importance of this residue for keeping the inhibitor in place.
We did not observe a measurable binding with Asp101Ala/
Tyr306Phe mutant (Fig 4E).
Furthermore, several of the most potent HDAC inhibitors—
despite the large diversity in the cap moiety—have two amides as
part of the cap ( Jones et al, 2006; Rodriquez et al, 2006), and are
therefore likely to establish such interactions with Asp101 in
HDAC8 or corresponding aspartic acid residues in other HDACs.
To this end, the importance of this interaction for drug-design
purposes is shown by structure-activity relationship studies of
HDAC1 inhibitors originating from a ketone variant (compound 1
in Jones et al, 2006 and in supplementary Table S2 online) of the
hydroxamic acid compound presented here. Inversion of the
stereocentre (compound 2), alkylation of either amides (com-
pounds 3 and 4), homologation of the chains to b-amino acids
(compounds 5 and 6) or main-chain shortening (compound 7) all
destroy the activity of these compounds (supplementary Table S2
online). In summary, the substrate-bound and the inhibitor-bound
structures presented here show the unexpected role of the
conserved Asp101 residue not only for HDAC substrate recogni-
tion, but also as a hotspot for drug design of new antitumour agents.
METHODS
See the supplementary information online for protein production
and activity assays, CD spectroscopy and thermal denaturation,
and SRP.
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Fig 4 | Biochemical data supporting the Asp101 interaction hypothesis. (A) Deacetylase assay on purified histones of wild-type HDAC8 and mutants.
(B) Thermally induced denaturation of wild-type HDAC8 and mutants by CD spectroscopy at 222 nm. The inhibitor is that used for crystallization,
whereas the substrate has no coumarin group, substituted instead with Leu-Met and corresponding to p53 protein sequence 379–384 (Liu et al, 1999).
(C–E) Surface plasmon resonance experiments of wild-type HDAC8 and mutants with the inhibitor. Protein concentration was 800 nM. Inhibitor
concentrations going from top to bottom are (C) 10, 5, 2.25, 1.25, 0.625, 0.3 and 0.15 mM, (D) 100, 50, 25, 12.5 and 6.25 mM and (E) 100, 50, 25
and 12.5 mM. The last curve is the Asp101Ala/Tyr306Phe mutant with 100mM inhibitor. CD spectroscopy, circular dichroism spectroscopy; HDAC,
histone deacetylase.
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Crystallization and diffraction data collection. HDAC8 point
mutants Tyr306Phe and Ser39Asp, in 50mM Tris–HCl (pH 8.0),
5% glycerol, 1mM dithiothreitol and 150mM KCl, were
concentrated to 217 mM and 150 mM, respectively. Tyr306Phe-
HDAC8 plus 3.2mM substrate was crystallized at 22 1C by
the hanging-drop method in 50mM Tris–HCl (pH 8.0), 50mM
MgCl2, 10% polyethylene glycol (PEG) 4000, 2mM tri(2-carboxy-
ethyl)phosphin (TCEP) and 30mM glycyl-glycyl-glycine. Crystals
were stabilized in 37.5mM Tris–HCl (pH 8.0), 75mM KCl, 25mM
MgCl2, 10% glycerol, 20% PEG 4000, 1mM TCEP and 50 mM
substrate and then frozen in liquid nitrogen after gradually
increasing PEG 4000 to 48%. For data collection, crystals were
annealed for two cycles in a drop containing the same amount of
cryoprotectant. Ser39Asp-HDAC8 plus 1.5mM inhibitor was
crystallized at 22 1C by the hanging-drop method in 50mM
2-(N-morpholino)ethanesulphonic acid (MES, pH 6.8), 4% PEG
20000, 2mM TCEP and 2% benzamidine. The Ser39Asp mutant
is active and folded like wild-type protein (data not shown),
and it was made for crystallization purposes because its
crystals diffract better than wild-type protein. Crystals were
stabilized in 25mM Tris–HCl (pH 8.0), 25mM MES (pH 6.8),
75mM KCl, 15% glycerol, 8% PEG 20000, 1mM TCEP and
100 mM inhibitor, before freezing them in liquid nitrogen by
increasing PEG 20000 to 12%. Data were collected at 100K
using 0.931 A˚ wavelength synchrotron radiation at ESRF,
Grenoble. Diffraction statistics are summarized in supplementary
Table SI online.
Structure determination and analysis. Both structures were
solved by molecular replacement with AMoRe (Navaza, 2001),
using the Protein Data Bank entry 1w22 as a search model
(Vannini et al, 2004). Dictionaries were generated with
PRODRG (Schuttelkopf & van Aalten, 2004). Model building
was carried out using QUANTA2000 (Accelrys, Cambridge, UK)
and refinement with REFMAC (Murshudov et al, 1997). Final
models encompass the following: for structure A (HDAC8–
substrate)—one HDAC8 dimer in the asymmetric unit (AU) with
each monomer consisting of residues 10–376 (A) or 15–377 (B),
one substrate molecule, one Zn2þ and two Kþ ions, plus one
glycyl-glycyl-glycine molecule in monomer B; for structure B
(HDAC8 inhibitor)—one HDAC8 dimer in the AU and each
monomer has residues 14–376, one inhibitor molecule, one Zn2þ
and two Kþ ions. Both models show good stereochemistry, as
assessed by PROCHECK (Laskowski, 2003), with 91% of total
residues in the most favoured regions and 9% in additionally
allowed regions of the Ramachandran plot, for structure A (90.5
and 9.5%, for structure B, respectively). Refinement statistics are
listed in supplementary Table SI online. Figures were generated
with PyMOL (DeLano Scientific).
Coordinates. The atomic coordinates and structure factors have
been deposited with the Protein Data Bank (accession codes 2v5w
and 2v5x).
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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